中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 11
Nov.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(11): 2137-2140

Toward zero mother-to-child transmission of hepatitis B virus： From controversy to consensus

DOI: 10.12449/JCH241101

  • Department of Infectious Diseases，Nanfang Hospital，Southern Medical University，Guangdong Provincial Institute of Liver Diseases，Guangzhou 510515，China

Research funding:

National Key Research and Development Program of China (2022YFC2303600)

More Information
  • Corresponding author: LIU Zhihua， zhihualiu@126.com （ORCID： 0000-0003-4398-4233）
  • Received Date: 2024-09-04
  • Accepted Date: 2024-09-18
  • Published Date: 2024-11-25
    Abstract
  • Mother-to-child transmission is the major route of transmission for hepatitis B virus （HBV）， and prevention of the mother-to-child transmission of HBV is the key link in the prevention and control of hepatitis B and one of the five essential core strategies for achieving the global elimination of hepatitis B by 2030. Combined immunization for neonates born to HBV-infected mothers and maternal antiviral intervention during pregnancy are important measures for blocking mother-to-child transmission， and thereby， the implementation of the comprehensive strategy of combined immunization and maternal antiviral intervention will help to accelerate the process of eliminating mother-to-child transmission. Chinese scholars have put forward the concept of “zero mother-to-child transmission of hepatitis B” and launched “Shield Program” in China， aiming to promote the implementation of the preventive strategy for mother-to-child transmission and lay a solid foundation for eliminating viral hepatitis in China. The Shield Program has provided detailed implementation strategies， successful practice experience， and reliable data for blocking the mother-to-child transmission of hepatitis B， fostering the consensus on the zero mother-to-child transmission of HBV in the academic community， and it also has an important reference value for eliminating the mother-to-child transmission of HBV in China and globally.

     

    • FullText(HTML)
  • loading
    • References(31)
  • [1]
    Working Committee of Promoting the Elimination of Viral Hepatitis of Chinese Preventive Medicine Association, Society of Prevention and Control of Infectious Diseases of Chinese Preventive Medicine Association. Expert recommendations on hepatitis B vaccination in adults[J]. J Clin Hepatol, 2024, 40( 8): 1551- 1556. DOI: 10.12449/JCH240808.

    中华预防医学会促进消除病毒性肝炎工作委员会, 中华预防医学会感染性疾病防控分会. 成人乙型肝炎疫苗接种专家建议[J]. 临床肝胆病杂志, 2024, 40( 8): 1551- 1556. DOI: 10.12449/JCH240808.
    [2]
    JING W, LIU J, LIU M. Eliminating mother-to-child transmission of HBV: progress and challenges in China[J]. Front Med, 2020, 14( 1): 21- 29. DOI: 10.1007/s11684-020-0744-2.
    [3]
    World Health Organization. Global hepatitis report 2024: action for access in low- and middle-income countries[R]. Geneva: World Health Organization, 2024.
    [4]
    HOU JL, WANG GQ, WANG FS, et al. Guideline of prevention and treatment for chronic hepatitis B(2015 update)[J]. J Clin Transl Hepatol, 2017, 5( 4): 297- 318. DOI: 10.14218/JCTH.2016.00019.
    [5]
    VISVANATHAN K, DUSHEIKO G, GILES M, et al. Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: Position paper produced by Australian, UK and New Zealand key opinion leaders[J]. Gut, 2016, 65( 2): 340- 350. DOI: 10.1136/gutjnl-2015-310317.
    [6]
    CHEN HL, LIN LH, HU FC, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV[J]. Gastroenterology, 2012, 142( 4): 773- 781. e 2. DOI: 10.1053/j.gastro.2011.12.035.
    [7]
    HAN GR, CAO MK, ZHAO W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection[J]. J Hepatol, 2011, 55( 6): 1215- 1221. DOI: 10.1016/j.jhep.2011.02.032.
    [8]
    ZHANG H, PAN CQ, PANG Q, et al. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice[J]. Hepatology, 2014, 60( 2): 468- 476. DOI: 10.1002/hep.27034.
    [9]
    PAN CQ, DUAN ZP, DAI EH, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load[J]. N Engl J Med, 2016, 374( 24): 2324- 2334. DOI: 10.1056/NEJMoa1508660.
    [10]
    ZENG QL, YU ZJ, JI FP, et al. Tenofovir alafenamide to prevent perinatal hepatitis B transmission: A multicenter, prospective, observational study[J]. Clin Infect Dis, 2021, 73( 9): e3324- e3332. DOI: 10.1093/cid/ciaa1939.
    [11]
    CUI FQ, WOODRING J, CHAN PL, et al. Considerations of antiviral treatment to interrupt mother-to-child transmission of hepatitis B virus in China[J]. Int J Epidemiol, 2018, 47( 5): 1529- 1537. DOI: 10.1093/ije/dyy077.
    [12]
    LIU ZH, LI ZD, YANG XZ, et al. Organizing an assembly to eliminate hepatitis B virus through a project zero mother-to-child transmission of hepatitis B virus[J]. Chin J Hepatol, 2019, 27( 2): 102- 105. DOI: 10.3760/cma.j.issn.1007-3418.2019.02.006.

    刘志华, 李增德, 杨希忠, 等. 乙型肝炎母婴零传播工程,向消除乙型肝炎的目标迈进[J]. 中华肝脏病杂志, 2019, 27( 2): 102- 105. DOI: 10.3760/cma.j.issn.1007-3418.2019.02.006.
    [13]
    YIN XR, LIU AH, HOU JL. Action for shield project promoting zero mother-to-child transmission of hepatitis B virus[J]. Chin J Hepatol, 2019, 27( 2): 81- 84. DOI: 10.3760/cma.j.issn.1007-3418.2019.02.001.

    尹雪如, 刘志华, 侯金林. 行动起来, 全力推动乙型肝炎母婴零传播工程[J]. 中华肝脏病杂志, 2019, 27( 2): 81- 84. DOI: 10.3760/cma.j.issn.1007-3418.2019.02.001.
    [14]
    YIN XR, LIU ZH, LIU ZH, et al. Getting to zero mother-to-child transmission of hepatitis B virus: Dream and challenge[J]. Chin J Hepatol, 2018, 26( 4): 262- 265. DOI: 10.3760/cma.j.issn.1007-3418.2018.04.006.

    尹雪如, 刘志华, 刘智泓, 等. 乙型肝炎病毒母婴零传播: 理想与挑战[J]. 中华肝脏病杂志, 2018, 26( 4): 262- 265. DOI: 10.3760/cma.j.issn.1007-3418.2018.04.006.
    [15]
    JOURDAIN G, NGO-GIANG-HUONG N, HARRISON L, et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B[J]. N Engl J Med, 2018, 378( 10): 911- 923. DOI: 10.1056/NEJMoa1708131.
    [16]
    LUO KX, CHEN JJ, LI P. Hepatitis basic biology and clinical science[M]. 4th ed. Beijing: People’s Medical Publishing House, 2012.

    骆抗先, 陈金军, 李平. 乙型肝炎基础和临床[M]. 4版. 北京: 人民卫生出版社, 2012.
    [17]
    Antiretroviral Pregnancy Registry Steering Committee. The antiretroviral pregnancy registry interim report(1 January 1989 through 31 Jan 2023)[R/OL].[ 2024-08-29]. https://www.apregistry.com/forms/interim_report.pdf. https://www.apregistry.com/forms/interim_report.pdf
    [18]
    FUNK AL, LU Y, YOSHIDA K, et al. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: A systematic review and meta-analysis[J]. Lancet Infect Dis, 2021, 21( 1): 70- 84. DOI: 10.1016/S1473-3099(20)30586-7.
    [19]
    BROWN RS Jr, MCMAHON BJ, LOK ASF, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis[J]. Hepatology, 2016, 63( 1): 319- 333. DOI: 10.1002/hep.28302.
    [20]
    HU Y, XU C, XU B, et al. Safety and efficacy of telbivudine in late pregnancy to prevent mother-to-child transmission of hepatitis B virus: A multicenter prospective cohort study[J]. J Viral Hepat, 2018, 25( 4): 429- 437. DOI: 10.1111/jvh.12834.
    [21]
    GREENUP AJ, TAN PK, NGUYEN V, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus[J]. J Hepatol, 2014, 61( 3): 502- 507. DOI: 10.1016/j.jhep.2014.04.038.
    [22]
    PAN CQ, DAI EH, DUAN ZP, et al. Long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil in China[J]. Gut, 2022, 71( 4): 798- 806. DOI: 10.1136/gutjnl-2020-322719.
    [23]
    FAN L, OWUSU-EDUSEI K Jr, SCHILLIE SF, et al. Cost-effectiveness of active-passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection[J]. Hepatology, 2016, 63( 5): 1471- 1480. DOI: 10.1002/hep.28310.
    [24]
    NAYAGAM S, de VILLIERS MJ, SHIMAKAWA Y, et al. Impact and cost-effectiveness of hepatitis B virus prophylaxis in pregnancy: A dynamic simulation modelling study[J]. Lancet Gastroenterol Hepatol, 2023, 8( 7): 635- 645. DOI: 10.1016/S2468-1253(23)00074-2.
    [25]
    ZHENG H, NAYAGAM S, CHAN PL, et al. Progress towards elimination of mother-to-child transmission of hepatitis B virus infection in China: A modelling analysis[J]. Bull World Health Organ, 2021, 99( 1): 10- 18. DOI: 10.2471/BLT.19.248146.
    [26]
    Chinese Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Management algorithm for interrupting mother-to-child transmission of hepatitis B virus(2021)[J]. J Clin Hepatol, 2021, 37( 3): 527- 531. DOI: 10.3969/j.issn.1001-5256.2021.03.007.

    中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会. 阻断乙型肝炎病毒母婴传播临床管理流程(2021年)[J]. 临床肝胆病杂志, 2021, 37( 3): 527- 531. DOI: 10.3969/j.issn.1001-5256.2021.03.007.
    [27]
    HOU JL, CUI FQ, DING Y, et al. Management algorithm for interrupting mother-to-child transmission of hepatitis B virus[J]. Clin Gastroenterol Hepatol, 2019, 17( 10): 1929- 1936. e 1. DOI: 10.1016/j.cgh.2018.10.007.
    [28]
    YIN XR, HAN GR, ZHANG H, et al. A real-world prospective study of mother-to-child transmission of HBV in China using a mobile health application(shield 01)[J]. J Clin Transl Hepatol, 2020, 8( 1): 1- 8. DOI: 10.14218/JCTH.2019.00057.
    [29]
    YIN XR, WANG W, CHEN H, et al. Real-world implementation of a multilevel interventions program to prevent mother-to-child transmission of HBV in China[J]. Nat Med, 2024, 30( 2): 455- 462. DOI: 10.1038/s41591-023-02782-x.
    [30]
    World Health Organization. Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy[R]. Geneva: World Health Organization, 2020.
    [31]
    Office of the National Health Commission. Notice on printing and distributing work specifications for prevention of mother to child transmission of AIDS, Syphilis and hepatitis B(2020 Edition)[EB/OL].( 2020-11-12)[ 2024-08-29]. http://www.nhc.gov.cn/fys/s3581/202011/fc7b46b2b48b45a69bd390ae3a62d065.shtml. http://www.nhc.gov.cn/fys/s3581/202011/fc7b46b2b48b45a69bd390ae3a62d065.shtml

    国家卫生健康委办公厅. 关于印发预防艾滋病、梅毒和乙肝母婴传播工作规范(2020年版)的通知[EB/OL].( 2020-11-12)[ 2024-08-29]. http://www.nhc.gov.cn/fys/s3581/202011/fc7b46b2b48b45a69bd390ae3a62d065.shtml. http://www.nhc.gov.cn/fys/s3581/202011/fc7b46b2b48b45a69bd390ae3a62d065.shtml
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (288) PDF downloads(138) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return